There is also a rationale for the use of CPIs in combination with EGFR-targeting antibodies such as cetuximab to treat other tumor types such as SCCHN and mCRC, with a predicted synergistic effect due to the ability of PD-L1 inhibitors to alleviate immunosuppression in the tumor microenvironment, and the ability of cetuximab to stimulate cells of the innate and adaptive immune system to induce anti-tumor ADCC (150). The gene discussed is CD274; the disease is neoplasm.